Silymarin is a hepatoprotective agent, having poor water solubility and oral absorption of about 23 – 47%, leading to low bioavailability of the drug. The aim of the present study is to improve the solubility and dissolution rate and in turn the hepatoprotective activity of the drug, by formulating its inclusion complex with beta (β)-cyclodextrin, using different methods. The phase solubility analysis indicates the formation of 1:1 molar inclusion complex of the drug with beta cyclodextrin. Apparent stability constant for Silymarin ($K_c$) was 722 K$^{-1}$ with β-cyclodextrin complex. The inclusion complexes were prepared by four different methods, namely, physical mixing, kneading, co-precipitation, and solvent evaporation. The prepared complexes were characterized using differential scanning colorimetry, scanning electron microscopy, and X-ray diffractometry. The inclusion complex prepared by the co-precipitation methods exhibits an overall best result, with respect to the formulation of sustained release formulations.

**Key words:** Bioavailability, inclusion complexes, silymarin, β-cyclodextrin
study. In addition, the physiochemical characteristics of solid inclusion complexes were also investigated.

**MATERIALS AND METHODS**

A gift sample of silymarin was obtained from AGAPE pharmaceuticals, Majhitar, East Sikkim; β-cyclodextrin was obtained from Zim Laboratories Ltd., Nagpur. HCl, methanol potassium dihydrogen phosphate, and sodium hydroxide were of analytical grade (Merck, Mumbai). All other chemicals and reagents used were of analytical grade.

**Phase solubility analysis for silymarin**

Phase solubility studies were performed to determine the stoichiometric proportions of silymarin with β-cyclodextrin. The data was used to determine the stability constant of the complexes. For this, the stock solution of 0.01 M β-cyclodextrin was prepared using distilled water. These stock solutions were diluted with distilled water to give molar solutions in the range of 0.002 to 0.01 M β-cyclodextrin. Five ml of each molar solution was filled in screw capped vials and the excess quantity of the drug was added to each vial separately. The vials were shaken at an ambient temperature, for 48 hours, using a laboratory shaker (Remi). The supernatant solutions were collected carefully and filtered using Whatman filter paper (No. 41). The concentration of the drug in filtered solutions was determined using a UV visible spectrophotometer. No changes in λ max of the drug were found after complexation with cyclodextrin, hence absorbance of the resultant solutions were recorded at 286 nm, which was λ max of the drug. From the slope and intercept value ($S_0$) of the phase solubility curve, a stability constant ($K_c$) was determined.

$$K_c = \frac{\text{Slope}}{[S_0 (1 - \text{Slope})]}$$

**Preparation of physical mixture and inclusion complexes**

**Physical mixture method**

The required molar (1 : 1) quantities of the drug and cyclodextrin were weighted accurately and mixed together thoroughly in a mortar, with vigorous trituration, for about three hours. These mixtures were then passed through sieve No. 44, and finally stored in airtight containers till further use.

**Kneading method**

The required quantities of the drug (Silymarin) and β-cyclodextrin were weighed accurately in a ratio of 1:1. A homogenous paste of cyclodextrin was prepared in a mortar by adding water : Methanol mixture (1 : 1) in small quantities. Silymarin powder was then added to this paste in portions, with continuous kneading, for three hours. An appropriate quantity of water : Methanol mixture (1:1) was added further to maintain suitable consistency of the paste. This paste was dried in a hot air oven at 45°–50° for 24 hours. The dried complexes were then powdered and passed through sieve No. 44 and stored in airtight containers till further use.

**Co-precipitation method**

Quantities of drug and cyclodextrin, in the required molar ratio (1 : 1), were dissolved in methanol : Water, respectively. The solution of the drug was added dropwise into cyclodextrin solution. The contents were continuously stirred for six hours and finally were dried at 45°–50° for 48 hours, collected, and stored in airtight containers till further use.

**Solvent evaporation method**

In this technique, silymarin along with solubilizing additives such as acetone were dissolved at 25°C temperature. Next, the required moles of β-cyclodextrin in hot distilled water were added dropwise into this solution, with continuous stirring, for one hour. The complexes formed were filtered and dried under a vacuum. Then the prepared solid mass was stored in a desiccator under vacuum to a constant weight. The dried products were removed, pulverized, and passed through sieve No. 100 and finally stored in a closed airtight container.

**Characterization of silymarin inclusion complexes**

**Drug content estimation**

The quantities of inclusion complex equivalent to 70 mg of silymarin were dissolved in water: Methanol mixture (1:1). Appropriate dilutions were made and the drug content of each complex was calculated from UV absorbance recorded at λ max 286 nm.

**Scanning electron microscopy**

The morphology of the inclusion complexes by physical mixture, kneading method, and co-precipitation method was studied using a scanning electron microscope (JSM-5610 LV Jeol, Japan). The samples were coated with platinum to provide a conductive layer for observing images at 15 kV.

**IR spectrum analysis**

Infra red (IR) spectra of the drug and inclusion complexes were recorded using the KBr method using Fourier Transform Infrared Spectrophotometer (FT IR-8400 S). A baseline
correction was made using dried potassium bromide, and then the spectra of the dried mixtures of drug and inclusion complexes with potassium bromide were recorded.

**Differential scanning calorimetric analysis**

This scanning was performed using DSC model (Perkin Elmer). The samples were placed in a closed platinum crucible and DSC thermograms were recorded at a heating rate of 10°/minute in the range of 20° to 310°C.[10]

**X-ray diffraction study**

The X-ray diffraction pattern of the selected inclusion complex was compared with that of pure silymarin. This was performed by measuring 2θ in the range of 4° to 50° with reproducibility of ±0°–001° on an X-ray diffractometer (Phillips).

**Dissolution study of silymarin and its inclusion complexes**

Dissolution of inclusion complexes (equivalent to 70 mg of silymarin) was studied using the USP XXII eight station dissolution apparatus (Electrolab TDT-08L). The dissolution was carried out in 900 ml of Phosphate buffer, pH 6.8, at a speed of 75 rpm. Aliquots of 10 mL were withdrawn periodically and replaced with 10 mL of fresh dissolution medium. The concentrations of the drug in the samples were determined by measuring their absorbance at 286 nm, using Shimadzu 1700 UV-visible spectrophotometer. Cumulative percent of the drug released was determined at every point of time. The pure drug was used as a control. The T₉₀ (time required for 90% dissolution of drug) of various solid dispersions were calculated.[17,18]

**RESULTS AND DISCUSSION**

**Phase solubility analysis of silymarin**

The phase solubility study was done to determine the stoichiometric proportion of silymarin with complexing agent β-cyclodextrin. The solubility analysis indicated the formation of a 1 : 1 molar inclusion complex of the drug with β-cyclodextrin. The apparent stability constant for silymarin (Kₐ) was 722 K⁻¹ with the β-cyclodextrin complex.

**Characterization of silymarin inclusion complexes**

All the inclusion complexes prepared using different methods, such as, physical mixture, kneading method, co-precipitation, and solvent evaporation method were found to be slightly brown, free-flowing powders.

**Estimation of drug content**

Inclusion complexes prepared by co-precipitation showed nearly 100% drug content. The drug content of the inclusion complex prepared by kneading, physical mixture, and solvent evaporation shows slightly less drug content as compared to that prepared by using co-precipitation [Table 1].

**Scanning electron microscopy**

Scanning electron microscopy (SEM) of the physical mixture method, inclusion complex by kneading method, and co-precipitation method were studied. The representative photographs are shown in Figures 1–3. Pure drug particles in the physical mixture method were very small in size with reduced effective surface area, due to agglomeration. They remained dispersed and physically adsorbed on the surface of β-cyclodextrin. Figures 2 and 3, show drug particles distributed on the surface of β-cyclodextrin. Both kneaded and the co-precipitated systems show a homogeneity, signifying the inclusion complex formation. The kneaded system is of poor crystal structure, lacks distinct crystal faces, and has numerous cracks and fissures. This may also have contributed to faster dissolution compared to the co-precipitation system.

**IR spectral analysis**

Infra red spectra of the pure drug and inclusion of

| Systems                        | % Drug content | T₉₀ (min) |
|--------------------------------|----------------|----------|
| Silymarin (alone)              | -              | <120     |
| Silymarin : β cyclodextrin (PM)| 97.140         | 62       |
| Silymarin : β cyclodextrin (KN)| 91.420         | 47       |
| Silymarin : β cyclodextrin (CP)| 99.995         | 94       |
| Silymarin : β cyclodextrin (SE)| 97.135         | 92       |

PM: Physical mixture, KN: Kneading, CP: Co-precipitation, SE: Solvent evaporation
Ghosh, et al.: Studies on silymarin molecular inclusion complexes

Figure 2: Silymarin with β-cyclodextrin (Kneading method)

Figure 3: Silymarin with β-cyclodextrin (Co-precipitation method)

Figure 4: IR spectra of inclusion complexes of silymarin with β-cyclodextrin (a) FT IR study of silymarin (b) Physical mixture method (c) Kneading method (d) Co-precipitation method (e) Solvent evaporation
Ghosh, et al.: Studies on silymarin molecular inclusion complexes

Table 2: Percentage cumulative release of inclusion complexes of silymarin and β-cyclodextrin prepared by different methods

| Time  | %CR (Silymarin) | %CR (PM) | %CR (KN) | %CR (CP) | %CR (SE) |
|-------|-----------------|----------|----------|----------|----------|
| 5     | 7.57            | 34.94    | 31.71    | 24.055   | 15.32    |
| 15    | 14.20           | 49.56    | 53.52    | 27.481   | 39.25    |
| 30    | 20.05           | 60.82    | 83.58    | 59.763   | 47.01    |
| 45    | 23.45           | 80.61    | 99.08    | 66.686   | 77.05    |
| 60    | 27.70           | 97.76    | -        | 69.520   | 84.23    |
| 75    | 32.79           | -        | -        | 87.200   | 86.41    |
| 90    | 43.67           | -        | -        | 93.455   | 98.80    |
| 105   | 46.34           | -        | -        | 95.320   | -        |
| 120   | 49.13           | -        | -        | -        | -        |

PM: Physical mixture, KN: Kneading, CP: Co-precipitation, SE: Solvent evaporation

Dissolution study of silymarin and its inclusion complexes

The inclusion complexes of silymarin with β-cyclodextrin produce pronounced enhancement in its dissolution as shown in Table 2 and Figure 7. From Table 1-T90 value for kneading shows the quickest rate of dissolution as compared to the other inclusion complexes, prepared by...
other inclusion methods. Inclusion complexes prepared by the co-precipitation methods show their T₀₉₀ in about 94 minutes.

CONCLUSION

The phase solubility data suggest a 1 : 1 complex formation with β-cyclodextrin. All inclusion complexes show increase in dissolution than in the drug alone. The inclusion complex of the drug prepared by the co-precipitation method shows the best results overall, in terms of drug content and dissolution profile, for preparation of sustained release formulations. However, it should be noted that this is a result of a preliminary study of β-cyclodextrin inclusion complexation with silymarin.

REFERENCES

1. Luper SA. Review of plants used in the treatment of liver disease, Part 1. Altern Med Rev 1998;3:410-21.
2. Pradhan SC, Girish C. Hepatoprotective herbal drug, Silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006;124:491-504.
3. Reynolds JE. Martindale the Extra Pharmacopoeia. London: Pharmaceutical Press; 2002.
4. Pepping J. Milk thistle: Silybum marianum. Am J Health Syst Pharm 1999;56:1195-7.
5. Saller R, Meier R, Brignoli R. The use of Silymarin in the treatment of liver diseases. Drugs 2001;61:2035-63.
6. Pinnamaneni S, Das N, Das SK. Formulation approaches for orally administered poorly soluble drugs. Pharmazie 2002;57:291-300.
7. Deshmukh SS, Potnis VV, Shelar DB, Mahaparale PR. Studies on inclusion complexes of ziprasone hydrochloride with β cyclodextrin and hydroxypropyl β cyclodextrin. Indian Drugs 2007;44:677-82.
8. Patil JS, Pandya NR, Marapur SC, Shiralashetti SS. Influence of method of preparation on physiochemical properties and in vitro drug release profile of nimodipine-β-cyclodextrin inclusion complexes: A comparative study. Int J Pharmacy Pharmaceutical Sci 2010;2:71-81.
9. Lofstrand T, Brewster ME, Masson M. Role of cyclodextrans in improving oral drug delivery. Am J Drug Deliv 2004;2:1-15.
10. Nagarsenkar MS, Meshram R, Ramprakash G. Solid dispersion of hydroxypropyl β cyclodextrin and Ketorolac: Enhancement of in vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenesis in rats. J Pharm Pharmacol 2000;52:949-56.
11. Reddy MN, Chowdary KP, Diwan PV. β-Cyclodextrin complexes of celecoxib: Molecular modeling, characterization and dissolution studies. AAPS Pharm Sci 2004;6:E7.
12. Lofstrand T, Brewster ME. Pharmaceutical application of cyclodextrin in drug solubilisation and stabilization. J Pharm Sci 1996;85:1017-25.
13. Kamal D, Ramana MD, Himaja M, Agarwal A, Garg V. Investigation of enhancement of solubility of norfloxacin beta cyclodextrin in presence of acidic solubilizing additives. Curr Drug Deliv 2007;4:21-5.
14. Atma AA, Nidhe ON, Nnamari PO. Studies on diclofenac-β-Cyclodextrin inclusion complexes. J Pharm Res 2004;3:47-9.
15. Soniwala MM, Patel PR, Ansuri MS, Patihk RK, Goel MC. Various approaches in dissolution enhancement of Rofecoxib. Indian J Pharm Sci 2005;67:61-7.
16. Aries MJ, Moyano JR, Munoz P, Justo A. Study of Omeprazole-γ cyclodextrin complexation in the solid state. Drug Dev Ind Pharm 2000;26:253-9.
17. Becket G, Schep LJ, Tan MY. Improvement of the in vitro dissolution of praziquantel by complexation with α-, β-, and γ-cyclodextrin. Int J Pharm 1999;179:65-71.
18. Beker O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJ. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm 1999;17:1503-40.

How to cite this article: Ghosh A, Biswas S, Ghosh T. Preparation and evaluation of silymarin β-cyclodextrin molecular inclusion complexes. J Young Pharmacists 2011;3:205-10.

Source of Support: Nil. Conflict of Interest: None declared.

Author Help: Online submission of the manuscripts

Articles can be submitted online from http://www.journalonweb.com. For online submission, the articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) First Page File:
Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should be included here. Use text/rtf/doc/pdf files. Do not zip the files.

2) Article File:
The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 1024 kb. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being incorporated in the article file. This will reduce the size of the file.

3) Images:
Submit good quality color images. Each image should be less than 4096 kb (4 MB) in size. The size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 6 inches and up to about 1800 x 1200 pixels). JPEG is the most suitable file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) Legends:
Legends for the figures/images should be included at the end of the article file.